Prime Medicine, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Prime Medicine, Inc. (PRME) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $59.64 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-03
- Prime Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $59.64M, a 1.47% decline from fiscal 2024.
- Prime Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $60.53M, a 5.97% increase from fiscal 2023.
- Prime Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $57.12M, a 54.88% increase from fiscal 2022.
- Prime Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $36.88M, a 46.04% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $59.64M 10-K · filed 2026-03-03 |
| 2024-12-31 | $60.53M 10-K · filed 2026-03-03 |
| 2023-12-31 | $57.12M 10-K · filed 2025-02-28 |
| 2022-12-31 | $36.88M 10-K · filed 2024-03-01 |
| 2021-12-31 | $25.25M 10-K · filed 2023-03-09 |
| 2020-12-31 | -$552.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |